NurseJet
Back to Discover
Research ArticleResearchMedication Safety

Older adults had comparable sacituzumab govitecan outcomes and severe toxicity in a selected real-world cohort

The Oncologist (PubMed)Jul 20, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

Across 18 Central European oncology centers, 76 adults age 65 or older receiving sacituzumab govitecan had response, treatment-modification, and grade 3 or higher neutropenia outcomes comparable to younger patients, while age was not independently associated with survival after adjustment.

What NurseJet pulled from the source

This retrospective multinational cohort included 303 adults with metastatic triple-negative breast cancer treated with sacituzumab govitecan, including 76 age 65 or older. Older patients had more comorbidities, more prior palliative treatment, and poorer performance status. Their unadjusted survival appeared longer, but age was not independently associated with overall or progression-free survival in multivariable models. Objective response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable by age. The authors attributed the unadjusted survival differences to baseline characteristics and selection rather than age itself.

Why this matters for nurses

Oncology nurses monitor treatment tolerance, laboratory trends, infection risk, and the practical effects of comorbidity and performance status. These data support individualized assessment rather than assuming that chronological age alone predicts poor tolerance or benefit.

Bedside takeaway

Selected older adults had comparable real-world outcomes and severe neutropenia, so tolerance assessment should extend beyond age alone.

How This Applies in Practice

Use this when: Caring for an older adult with metastatic triple-negative breast cancer who is receiving a provider-directed sacituzumab govitecan regimen.

On your shift

  • Review ordered laboratory results, current symptoms, comorbidities, functional status, and recent treatment interruptions before administration.
  • Assess for infection or treatment intolerance and escalate fever, clinical deterioration, or abnormal results through the oncology team promptly.
  • Document tolerance trends and how symptoms affect function so dose and supportive-care decisions reflect more than chronological age.
Keep in mind: Do not infer safety for every older or frail adult from this selected retrospective cohort. Follow the antineoplastic protocol, facility policy, and patient-specific provider orders.

Explain this for my unit

Key takeaways

  • The real-world cohort included 303 patients treated at 18 oncology centers, with 76 patients age 65 or older.
  • Response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable between age groups.
  • Chronological age was not independently associated with overall or progression-free survival after adjustment.
  • The selected older group and retrospective design limit conclusions about frailer adults or causal treatment effects.

Practice implications

  • Review ordered blood counts and current symptoms before treatment, assess how comorbidities and functional status affect the care plan, and escalate fever, infection concerns, or suspected treatment toxicity promptly. Communicate trends and treatment interruptions so the oncology team can make patient-specific dosing and supportive-care decisions.

Limitations & cautions

  • This was a retrospective study of a selected treated population across Central European centers, and only 76 patients were age 65 or older. Age 65 does not capture frailty, selection into treatment may explain apparent similarities, and residual confounding remains. The abstract reports severe neutropenia but does not provide a complete age-stratified adverse-event profile.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Oncologist (PubMed)

The Oncologist (PubMed). Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42477865/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

EClinicalMedicine (PubMed)Practice applicable

A JBI scoping review of 52 publications mapped nursing roles across precision cancer care and found uneven alignment between expanding competency expectations and available education, particularly for autonomous, interpretive, leadership, and governance responsibilities.

OncologyLeadershipAI summaryReview source

Nursing open (PubMed)Practice applicable

A randomized trial of 170 adults scheduled for intestinal stoma surgery found that adding practice with a wearable stoma-care training belt to standard preoperative education improved self-care skills, adjustment, anxiety, and education satisfaction through 30 days after discharge.

Med-SurgAI summaryReview source

Critical care nursing clinics of North America (PubMed)Practice applicable

A clinical review describes ICU nurses as central to coordinated prevention of multidrug-resistant organism transmission through stewardship, pathogen surveillance, appropriate isolation precautions, and evidence-based hygiene practices.

ICUMed-SurgAI summaryReview source